Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.72 |
| ▸ | HPGD | P15428 | 3/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.52 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
| ▸ | MGLL | Q99685 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3528928 | 0.98 | RXFP1 (0.70) | RXFP1HPGDUSP2HSP90AA1P2RX7 | |
| Tert-Butyl Formate SCHEMBL27697849 | 0.87 | RXFP1 (0.55) | RXFP1HPGDUSP2HSP90AA1P2RX7 | |
| SCHEMBL23793444 | 0.86 | HPGD (0.73) | RXFP1HPGDUSP2P2RX7MGLL | |
| SCHEMBL15567382 | 0.84 | RXFP1 (0.77) | RXFP1HSP90AA1P2RX7SIGMAR1RAB9A | |
| SCHEMBL5354871 | 0.84 | HPGD (0.73) | RXFP1HPGDP2RX7SIGMAR1HRH4 | |
| SCHEMBL6673835 | 0.84 | RXFP1 (1.00) | RXFP1HPGDHSP90AA1SIGMAR1MGLL | |
| SCHEMBL15016022 | 0.83 | HPGD (0.56) | RXFP1HPGDUSP2P2RX7MGLL | |
| SCHEMBL29432644 | 0.82 | HPGD (0.55) | RXFP1HPGDSIGMAR1MGLLHRH4 | |
| SCHEMBL3528330 | 0.79 | P2RX7 (0.55) | RXFP1HPGDP2RX7SIGMAR1HRH4 | |
| SCHEMBL13031082 | 0.79 | RXFP1 (0.52) | RXFP1HPGDUSP2HSP90AA1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1813609-B1 | NOVEL AMINOPYRIDINE DERIVATIVES HAVING SELECTIVE AURORA-A INHIBITORY EFFECT | MSD KK (JP) | 2013-06-19 | — | — | EP | disclosed |
| EP-1813609-B1 | NOVEL AMINOPYRIDINE DERIVATIVES HAVING SELECTIVE AURORA-A INHIBITORY EFFECT | MSD KK (JP) | 2013-06-19 | — | — | EP | disclosed |
| EP-1828165-B1 | NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION | MSD KK (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1828165-B1 | NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION | MSD KK (JP) | 2013-03-20 | — | — | EP | disclosed |
| US-7834018-B2 | aurora kinase inhibitors; 2-(thiazol-2-ylamino)pyridine compounds as antitumor agents; 6-((4-(3-chloro-2-fluorobenzoyl)piperazin-1-yl)methyl)-N-thiazol-2-ylpyridin-2-amine for example | BANYU PHARMACEUTICAL CO., LTD (JP) | 2010-11-16 | — | — | US | disclosed |
| US-7834018-B2 | aurora kinase inhibitors; 2-(thiazol-2-ylamino)pyridine compounds as antitumor agents; 6-((4-(3-chloro-2-fluorobenzoyl)piperazin-1-yl)methyl)-N-thiazol-2-ylpyridin-2-amine for example | BANYU PHARMACEUTICAL CO., LTD (JP) | 2010-11-16 | — | — | US | disclosed |
| US-7834018-B2 | aurora kinase inhibitors; 2-(thiazol-2-ylamino)pyridine compounds as antitumor agents; 6-((4-(3-chloro-2-fluorobenzoyl)piperazin-1-yl)methyl)-N-thiazol-2-ylpyridin-2-amine for example | BANYU PHARMACEUTICAL CO., LTD (JP) | 2010-11-16 | — | — | US | disclosed |
| US-20090149470-A1 | Novel aminopyridine derivatives having aurora a selective inhibitory action | MSD K.K. (JP) | 2009-06-11 | — | — | US | disclosed |
| US-20090149470-A1 | Novel aminopyridine derivatives having aurora a selective inhibitory action | MSD K.K. (JP) | 2009-06-11 | — | — | US | disclosed |
| US-20090149470-A1 | Novel aminopyridine derivatives having aurora a selective inhibitory action | MSD K.K. (JP) | 2009-06-11 | — | — | US | disclosed |
| US-7491720-B2 | Aminopyridine derivatives having Aurora A selective inhibitory action | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-02-17 | — | — | US | disclosed |
| US-20080027042-A1 | Novel Aminopyridine Derivatives Having Aurora a Selective Inhibitory Action | OHKUBO MITSURU | 2008-01-31 | — | — | US | disclosed |
| US-20080027042-A1 | Novel Aminopyridine Derivatives Having Aurora a Selective Inhibitory Action | OHKUBO MITSURU | 2008-01-31 | — | — | US | disclosed |
| US-20080027042-A1 | Novel Aminopyridine Derivatives Having Aurora a Selective Inhibitory Action | OHKUBO MITSURU | 2008-01-31 | — | — | US | disclosed |
| CN-101103017-A | Novel aminopyridine derivatives having Aurora-A selective inhibitory action | BANYU PHARMA CO LTD (JP) | 2008-01-09 | — | — | CN | disclosed |
| EP-1828165-A1 | NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-09-05 | — | — | EP | disclosed |
| EP-1813609-A2 | NOVEL AMINOPYRIDINE DERIVATIVES HAVING SELECTIVE AURORA-A INHIBITORY EFFECT | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-08-01 | — | — | EP | disclosed |
| EP-1813609-A2 | NOVEL AMINOPYRIDINE DERIVATIVES HAVING SELECTIVE AURORA-A INHIBITORY EFFECT | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-08-01 | — | — | EP | disclosed |
| US-20060106029-A1 | Novel aminopyridine derivatives having aurora a selective inhibitory action | MSD K.K. (JP) | 2006-05-18 | — | — | US | disclosed |
| WO-2006046735-A1 | NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027042-A1 | Novel Aminopyridine Derivatives Having Aurora a Selective Inhibitory Action | AURKA, AURKC, AURKB | RXFP1 1124/4885HPGD 3822/4885USP2 3350/4885 |
| US-20060106029-A1 | Novel aminopyridine derivatives having aurora a selective inhibitory action | AURKA, AURKC, AURKB | RXFP1 1124/4885HPGD 3822/4885USP2 3350/4885 |
| US-20090149470-A1 | Novel aminopyridine derivatives having aurora a selective inhibitory action | AURKA, AURKC, AURKB | RXFP1 1124/4885HPGD 3822/4885USP2 3350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.